Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and mass balance of BAY 2927088 in healthy men
NCT06221475Phase 1Completed
- Sponsor
- Bayer
- Start
- Jan 2024
- Primary completion
- Apr 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sevabertinib in non-small cell lung cancer (NSCLC), sponsored by Bayer. Primary endpoints: Absolute bioavailability (F), Area under the concentration curve and 3 more. Started Jan 2024; status: completed.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06221475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221475.